0001209191-24-005118.txt : 20240327
0001209191-24-005118.hdr.sgml : 20240327
20240327205215
ACCESSION NUMBER: 0001209191-24-005118
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20240327
FILED AS OF DATE: 20240327
DATE AS OF CHANGE: 20240327
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Mancini Marianna
CENTRAL INDEX KEY: 0001838112
ORGANIZATION NAME:
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-37355
FILM NUMBER: 24793071
MAIL ADDRESS:
STREET 1: C/O VIKING THERAPEUTICS, INC.
STREET 2: 12340 EL CAMINO REAL, STE 250
CITY: SAN DIEGO
STATE: CA
ZIP: 92130
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Viking Therapeutics, Inc.
CENTRAL INDEX KEY: 0001607678
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
ORGANIZATION NAME: 03 Life Sciences
IRS NUMBER: 461073877
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 9920 PACIFIC HEIGHTS BLVD, SUITE 350
CITY: SAN DIEGO
STATE: CA
ZIP: 92121
BUSINESS PHONE: 858-704-4660
MAIL ADDRESS:
STREET 1: 9920 PACIFIC HEIGHTS BLVD, SUITE 350
CITY: SAN DIEGO
STATE: CA
ZIP: 92121
4
1
doc4.xml
FORM 4 SUBMISSION
X0508
4
2024-03-27
0
0001607678
Viking Therapeutics, Inc.
VKTX
0001838112
Mancini Marianna
C/O VIKING THERAPEUTICS, INC.
9920 PACIFIC HEIGHTS BLVD, SUITE 350
SAN DIEGO
CA
92121
0
1
0
0
Chief Operating Officer
0
Common Stock, par value $0.00001 per share
2024-03-27
4
A
0
31667
0.00
A
380175
D
Common Stock, par value $0.00001 per share
2024-03-27
4
F
0
16610
83.34
D
363565
D
The reported securities were subject to a performance restricted stock unit award that was granted on January 3, 2023, 33.33% of which vested on March 27, 2024 upon the achievement of a non-financial performance goal.
These shares were withheld by the Issuer in order to satisfy certain tax withholding obligations in connection with the issuance of shares upon
the vesting of certain shares of common stock subject to certain performance restricted stock units.
/s/ Michael Morneau, as Attorney-in-Fact
2024-03-27